Raipur, December 17, 2025 — The Food and Drug Administration (FDA) has launched a major crackdown on the circulation of spurious and substandard medicines that are suspected to be moving illegally in the market. Acting on specific intelligence, the department intercepted a suspicious consignment at Nagpur Golden Transport, Gogawn, Raipur (Chhattisgarh), which was neither claimed by any individual nor received by any retail outlet, raising concerns about the authenticity of the medicines.
Taking the matter seriously, an inspection team was constituted under the provisions of the Drugs and Cosmetics Act, 1940. During the inspection, officials examined the consignment and related documents for medicines dispatched from Indore. It was found that the medicines mentioned in the invoice were not present in the consignment, and instead three other types of medicines were recovered.
Samples of the seized medicines were drawn in accordance with procedure—divided into four parts each—and the remaining stock was seized. The samples were sent to the State Drug Testing Laboratory, Kalibadi, Raipur, for analysis. Further investigation is underway to trace the actual source, supply chain, and any potential illegal activities linked to the consignment.
In continuation of the action, reports issued by the State Drug Testing Laboratory on December 16, 2025, confirmed that all three medicines were found to be spurious and substandard. The drugs were purportedly manufactured by:
M/s G Biotech Pvt. Ltd., Nahan Road, Solan, Himachal Pradesh
M/s G.C. Health Care, Solan, Himachal Pradesh
M/s Lar Ox Pharmaceuticals, Gopalakrishnan, Chennai
Following the findings, the Food and Drug Administration, Chhattisgarh, has issued alerts to the Central Drugs Standard Control Organization (CDSCO), New Delhi, and to officials across all districts of the state. Instructions have been issued to initiate strict legal action in accordance with rules, keeping in view the possible transportation and market availability of substandard medicines.
The department has appealed to the general public, drug retailers, and transport agencies to immediately report any suspicious medicines or irregular activities to the FDA helpline at +91 9340597097. Stakeholders have also been advised to procure and supply medicines only from licensed and reliable sources.
